Drug Profile
Research programme: antibody therapeutics - Genmab/Roche
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Genmab; Roche
- Class Antibodies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer; Inflammation; Respiratory tract disorders; Vascular disorders
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Europe (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Inflammation in Europe (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Respiratory-tract-disorders in Europe (Parenteral)